Conatus Pharmaceuticals Inc (NASDAQ:CNAT) – SunTrust Banks issued their Q1 2018 EPS estimates for Conatus Pharmaceuticals in a research note issued on Thursday. SunTrust Banks analyst J. Boris forecasts that the biotechnology company will post earnings per share of ($0.22) for the quarter. SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.25) EPS, Q4 2018 earnings at ($0.26) EPS, FY2021 earnings at $2.44 EPS and FY2022 earnings at $6.69 EPS.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02. The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $9.60 million. Conatus Pharmaceuticals had a negative return on equity of 61.39% and a negative net margin of 49.17%.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at $7.27 on Friday. The company has a market capitalization of $218.14, a PE ratio of -11.92 and a beta of 1.28. Conatus Pharmaceuticals has a one year low of $3.88 and a one year high of $9.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Voya Investment Management LLC acquired a new stake in Conatus Pharmaceuticals during the second quarter valued at approximately $101,000. Wells Fargo & Company MN raised its stake in Conatus Pharmaceuticals by 3,098.0% during the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 18,588 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of Conatus Pharmaceuticals by 156.4% during the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 14,700 shares during the last quarter. Stone Ridge Asset Management LLC bought a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at approximately $143,000. Finally, California State Teachers Retirement System bought a new position in shares of Conatus Pharmaceuticals during the second quarter valued at approximately $261,000. Hedge funds and other institutional investors own 39.57% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Conatus Pharmaceuticals Inc (CNAT) to Post Q1 2018 Earnings of ($0.22) Per Share, SunTrust Banks Forecasts” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3252350/conatus-pharmaceuticals-inc-cnat-to-post-q1-2018-earnings-of-0-22-per-share-suntrust-banks-forecasts.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.